[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599934":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":25,"locations":35,"responsibleParty":53,"collaborators":18,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":59,"sex":65,"minAge":66,"maxAge":18,"enrollmentInfo":67,"targetDuration":18,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":79,"overallStatus":38,"whyStopped":18,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"The First Affiliated Hospital of Hainan Medical University","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Endovascular Treatment Group","EXPERIMENTAL","Endovascular treatment procedures will be performed in accordance with each center's standard operating protocols. Based on the characteristics of vascular lesions and clinical judgment, investigators may select appropriate interventions for stenosis or occlusion, including stent retriever thrombectomy, aspiration thrombectomy, balloon angioplasty, stenting, intra-arterial thrombolysis, or various combinations of these methods.",[13],"Procedure: Endovascular Treatment",{"label":15,"type":16,"description":17,"interventionNames":18},"Best Medical Management Group","NO_INTERVENTION","Participants receive the best medical management only. Best Medical Treatment and maximum supportive care according to local guidelines, not including mechanical thrombectomy or intra-arterial treatment.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"PROCEDURE","Endovascular Treatment","The vascular access route is selected based on the patient's anatomical characteristics and operator discretion. Endovascular treatment (EVT) procedures must adhere to each participating center's standardized operating protocols. Upon confirmation of vascular occlusion, EVT may be performed using devices approved by China's National Medical Products Administration (NMPA). Based on lesion-specific features and operator judgment, permissible techniques include stent retriever thrombectomy, aspiration thrombectomy, balloon angioplasty with or without stenting, or intra-arterial thrombolysis. Investigational devices are strictly prohibited.",[9],[26,31],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},"Zhengqiang Zhao, PhD","CONTACT","8613976015677","zhenqiang.zhao@qq.com",{"name":32,"role":28,"phone":33,"phoneExt":18,"email":34},"Wen Sun, PhD","8615050589620","sunwen_medneuro@163.com",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"First Affiliated Hospital of Hainan Medical University","RECRUITING","Haikou","Hainan","570100","China","CN",{"type":45,"coordinates":46},"Point",[47,48],110.34651,20.03421,{"lat":48,"lon":47},[51,52],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},{"name":32,"role":28,"phone":18,"phoneExt":18,"email":34},{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","zhaozhenqiang","Principal Investigator","100599934","evt-in-acute-basilar-artery-occlusion-with-large-infarction-core-100599934",false,"NCT07090941","EVT in Acute Basilar Artery Occlusion With Large Infarction Core","Trial of Endovascular Treatment in Acute Basilar Artery Occlusion Patients With a Large Infarct Core","BOLT","Inclusion Criteria:\n\n* 1\\. Age ≥18 years. 2. Symptoms and signs consistent with basilar artery ischemia. 3. Basilar artery or vertebral artery occlusion confirmed by computed tomography angiography (CTA), magnetic resonance angiography (MRA), digital subtraction angiography (DSA); if vertebral artery occlusion is present, it must completely obstruct blood flow to the basilar artery.\n\n  4\\. POST-NIHSS score ≥10 at randomization. 5. Time from symptom onset to randomization ≤24 hours (symptom onset defined as last known well time).\n\n  6\\. pc-ASPECTS of 3-5 on CT\u002FMRI (for patients aged \\\u003C80 years) or pc-ASPECTS of 3-7 (for patients aged ≥80 years).\n\n  7\\. Willingness of the patient or legally authorized representative to comply with protocol requirements and data collection procedures, with documented informed consent.\n\nExclusion Criteria:\n\n* 1\\. Pre-stroke modified Rankin Scale (mRS) score \\>2. 2. Factors in the target vessel that are expected to prevent completion of endovascular treatment.\n\n  3\\. Concurrent anterior and posterior circulation strokes or multivessel occlusions.\n\n  4\\. Significant mass effect with imaging or clinical signs of obstructive hydrocephalus or tonsillar herniation.\n\n  5\\. Basilar artery occlusion confirmed as chronic by prior imaging or investigator judgment.\n\n  6\\. Presence of untreated intracranial aneurysms, intracranial tumors (except small meningiomas), or intracranial vascular malformations.\n\n  7\\. Intracranial hemorrhage within the past 6 months, including parenchymal brain hemorrhage, intraventricular hemorrhage, or subarachnoid hemorrhage.\n\n  8\\. Presence of active bleeding, coagulation disorders, or uncorrectable bleeding tendencies.\n\n  9\\. Severe heart, liver, or kidney dysfunction or other severe systemic late-stage diseases.\n\n  10\\. Known allergy to iodine contrast agents or other treatment-related drugs. 11. Medically uncontrolled refractory hypertension (defined as persistent systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg) (Note: Participants can be included if their blood pressure is controllable with medication and maintained at an acceptable level).\n\n  12\\. Uncontrollable blood glucose \\\u003C2.8 mmol\u002FL or \\>22.2 mmol\u002FL. 13. Pregnancy or breastfeeding. 14. Life expectancy \\\u003C6 months. 15. Participation in other clinical studies that may affect outcome assessment. 16. Investigator's judgment that the patient is unsuitable for participation in this study or may face significant risks (e.g., due to mental illness, cognitive, or emotional disorders preventing understanding and\u002For compliance with study procedures and\u002For follow-up).","ALL","18 Years",{"count":68,"type":69},348,"ESTIMATED","INTERVENTIONAL",[72],"NA","A multicenter, prospective, open-label, blinded endpoint, randomized controlled trial designed to evaluate the efficacy and safety of best medical management (BMM) combined with endovascular treatment (EVT) versus BMM alone in acute basilar artery occlusion (BAO) patients with large infarct cores.",[75,76,77,78],"Basilar Artery Occlusion","Large Ischemic Core","Large Core Infarct","Endovascular Treatments",[75,80,81],"Endovascular treatment","Large infarct core","2025-07-21",{"date":84,"type":85},"2025-07-29","ACTUAL",{"date":87,"type":69},"2025-08-01",{"date":89,"type":69},"2027-12-31",{"name":5,"class":6},1]